• SPX
  • $5,751.07
  • 0.9 %
  • $51.13
  • DJI
  • $42,352.75
  • 0.81 %
  • $341.16
  • N225
  • $38,635.62
  • 0.22 %
  • $83.56
  • FTSE
  • $8,280.63
  • -0.02 %
  • -$1.89
  • IXIC
  • $18,137.85
  • 1.22 %
  • $219.38
Centessa Pharmaceuticals plc (CNTA) Stock Price, News & Analysis

Centessa Pharmaceuticals plc (CNTA) Stock Price, News & Analysis

Currency in USD Disclaimer

$15.92

$0.04

(0.25%)

Day's range
$15.57
Day's range
$16.3
50-day range
$9.1
Day's range
$17.59
  • Country: GB
  • ISIN: US1523091007
52 wk range
$5.33
Day's range
$17.59
  • CEO: Dr. Saurabh Saha M.D., Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 6.44
  • Piotroski Score 4.00
  • Grade Buy
  • Symbol (CNTA)
  • Company Centessa Pharmaceuticals plc
  • Price $15.92
  • Changes Percentage (0.25%)
  • Change $0.04
  • Day Low $15.57
  • Day High $16.30
  • Year High $17.59

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/11/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $20.00
  • High Stock Price Target $26.00
  • Low Stock Price Target $19.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.42
  • Trailing P/E Ratio -6.2
  • Forward P/E Ratio -6.2
  • P/E Growth -6.2
  • Net Income $-151,670,616

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.